{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:58:40Z","timestamp":1793314720994,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.jbior.2022.100917","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T02:25:16Z","timestamp":1664418316000},"page":"100917","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3156","authenticated-orcid":false,"given":"James A.","family":"McCubrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde Y.","family":"Follo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Manzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melchiorre","family":"Cervello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbior.2022.100917_bib1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-018-0616-2","article-title":"Randomized, phase I\/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma","volume":"11","author":"Abdel-Wahab","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.jbior.2022.100917_bib2","article-title":"Potential benefit of treatment with MEK inhibitors and chemotherapy in BRAF-mutated KRAS wild-type pancreatic ductal adenocarcinoma patients: a case report","volume":"7","author":"Ardalan","year":"2021","journal-title":"CSH mol. case studies"},{"key":"10.1016\/j.jbior.2022.100917_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3390\/cancers13081781","article-title":"Therapeutic application of monoclonal antibodies in pancreatic cancer: Advances, challenges and future opportunities","volume":"13","author":"Arias-Pinilla","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2022.100917_bib4","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/CMR.0000000000000821","article-title":"A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-\/MEK-inhibitors and immune checkpoint inhibitors","volume":"32","author":"Awada","year":"2022","journal-title":"Melanoma Res."},{"key":"10.1016\/j.jbior.2022.100917_bib5","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1080\/15548627.2022.2038899","article-title":"Clinical trial results show promise of targeting autophagy BRAF mutant melanoma","volume":"18","author":"Amaravadi","year":"2022","journal-title":"Autophagy"},{"key":"10.1016\/j.jbior.2022.100917_bib6","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.3171\/foc.2003.14.2.4","article-title":"Therapy of glioblastoma multiforme improved by the antimutagenic chloroquine","volume":"14","author":"Brice\u00f1o","year":"2003","journal-title":"Neurosurg. Focus"},{"key":"10.1016\/j.jbior.2022.100917_bib7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1186\/s12885-018-4584-2","article-title":"Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps","volume":"18","author":"Boone","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jbior.2022.100917_bib8","series-title":"Hydroxychloroquine and Chloroquine Retinopathy","article-title":"Pharmacology of chloroquine and hydroxychloroquine","author":"Browning","year":"2014"},{"key":"10.1016\/j.jbior.2022.100917_bib9","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41591-019-0368-8","article-title":"Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer","volume":"25","author":"Bryant","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbior.2022.100917_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jbior.2018.02.002","article-title":"Metformin influences drug sensitivity in pancreatic cancer cells","volume":"68","author":"Candido","year":"2018","journal-title":"Adv. Biolog. Reg."},{"key":"10.1016\/j.jbior.2022.100917_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2022.100917_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41467-018-03225-9","article-title":"Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype","volume":"9","author":"Chen","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbior.2022.100917_bib14","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jamaoncol.2016.5383","article-title":"Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial","volume":"3","author":"Chung","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib15","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/15548627.2017.1280223","article-title":"Tumor cell-intrinsic CD274\/PD-L1: a novel metabolic balancing act with clinical potential","volume":"13","author":"Clark","year":"2017","journal-title":"Autophagy"},{"key":"10.1016\/j.jbior.2022.100917_bib16","doi-asserted-by":"crossref","first-page":"15 75","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the groupe Francophone des my\u00e9lodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib17","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12967-022-03462-z","article-title":"Inhibition of autophagy by chloroquine prevents resistance to PI3K\/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models","volume":"20","author":"Cocco","year":"2022","journal-title":"J. Trans. Med."},{"key":"10.1016\/j.jbior.2022.100917_bib18","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/ijc.27916","article-title":"Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death","volume":"132","author":"Conradt","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbior.2022.100917_bib19","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.18632\/oncotarget.2209","article-title":"Deregulation of the EGFR\/PI3K\/PTEN\/Akt\/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention","volume":"5","author":"Davis","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2022.100917_bib20","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.3390\/cancers13163946","article-title":"Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical Updates","volume":"13","author":"De Lellis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2022.100917_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ccell.2020.05.010","article-title":"Altered RNA splicing by mutant p53 activates oncogenic RAS signaling in pancreatic cancer","volume":"38","author":"Escobar-Hoyos","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jbior.2022.100917_bib22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14728214.2017.1293648","article-title":"Emerging protein kinase inhibitors for treating pancreatic cancer","volume":"22","author":"Furuse","year":"2017","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.jbior.2022.100917_bib23","first-page":"473","article-title":"Chloroquine-induced autophagic vacuole accumulation and cell death in glioma cells is p53 independent","volume":"12","author":"Geng","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.pmbts.2016.09.008","article-title":"Molecular pathogenesis of pancreatic cancer","volume":"144","author":"Grant","year":"2016","journal-title":"Prog. Mole. Biol. Trans. Sci."},{"key":"10.1016\/j.jbior.2022.100917_bib25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-Mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbior.2022.100917_bib26","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1038\/s41467-019-12555-1","article-title":"Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia","volume":"10","author":"Hayashi","year":"2019","journal-title":"Nat. Com."},{"key":"10.1016\/j.jbior.2022.100917_bib27","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C Inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"NEJM"},{"key":"10.1016\/j.jbior.2022.100917_bib28","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","article-title":"Pancreatic cancer: a review of epidemiology, trend, and risk factors","volume":"27","author":"Hu","year":"2021","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jbior.2022.100917_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.jbior.2022.100917_bib30","doi-asserted-by":"crossref","first-page":"9694","DOI":"10.3748\/wjg.v22.i44.9694","article-title":"Epidemiology of pancreatic cancer","volume":"22","author":"Ilic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jbior.2022.100917_bib31","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.ejca.2014.04.024","article-title":"A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas","volume":"50","author":"Infante","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbior.2022.100917_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1517\/14728222.2016.1085971","article-title":"The potential of Beclin 1 as a therapeutic target for the treatment of breast cancer","volume":"20","author":"Jung","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jbior.2022.100917_bib33","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1001\/jamaoncol.2019.0684","article-title":"Effect of gemcitabine and nab-Paclitaxel with or without Hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial","volume":"5","author":"Karasic","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib34","first-page":"4294","article-title":"A prognostic score based on long-term survivor unique transcriptomic signatures predicts patient survival in pancreatic ductal adenocarcinoma","volume":"11","author":"Katsuta","year":"2021","journal-title":"Amer. J. Cancer Res."},{"key":"10.1016\/j.jbior.2022.100917_bib35","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/neuonc\/nop046","article-title":"Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells","volume":"12","author":"Kim","year":"2010","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: a pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jbior.2022.100917_bib37","first-page":"620","article-title":"Protective autophagy elicited by RAF\u2192MEK\u2192ERK inhibition suggests a treatment strategy for RAS-driven cancers","volume":"25","author":"Kinsey","year":"2019","journal-title":"Nat. Med. (N. Y., NY, U. S.)"},{"key":"10.1016\/j.jbior.2022.100917_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/cancers10010024","article-title":"Contemporary management of localized resectable pancreatic cancer","volume":"10","author":"Kommalapati","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2022.100917_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4161\/auto.2.2.2463","article-title":"Autophagy and cancer therapy","volume":"2","author":"Kondo","year":"2006","journal-title":"Autophagy"},{"key":"10.1016\/j.jbior.2022.100917_bib40","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/s41375-020-0949-z","article-title":"MDM2 inhibition: an important step forward in cancer therapy","volume":"34","author":"Konopleva","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2022.100917_bib41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000330194","article-title":"KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine\/oxaliplatin (GEMOXCET) in first-line therapy","volume":"81","author":"Kullmann","year":"2011","journal-title":"Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib42","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1210\/jc.2017-00627","article-title":"Pituitary tumor suppression by combination of cabergoline and chloroquine","volume":"102","author":"Lin","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jbior.2022.100917_bib43","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/aps.2014.3","article-title":"Chloroquine potentiates the anti-cancer effect of lidamycin on non-small cell lung cancer cells in vitro","volume":"35","author":"Liu","year":"2014","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.jbior.2022.100917_bib44","article-title":"Chloroquine and hydroxychloroquine for cancer therapy","volume":"1","author":"Manic","year":"2014","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib45","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1038\/leu.2008.207","article-title":"Involvement of p53 and Raf\/MEK\/ERK pathways in hematopoietic drug resistance","volume":"22","author":"McCubrey","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jbior.2022.100917_bib46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.18632\/aging.101250","article-title":"Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs","volume":"9","author":"McCubrey","year":"2017","journal-title":"Aging"},{"key":"10.1016\/j.jbior.2022.100917_bib47","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/cells11142155","article-title":"Effects of TP53 mutations and miRs on immune responses in the tumor microenvironment important in pancreatic cancer progression","volume":"11","author":"McCubrey","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jbior.2022.100917_bib48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/biom12020276","article-title":"APR-246-The mutant TP53 reactivator-Increases the effectiveness of berberine and modified berberines to Inhibit the proliferation of pancreatic cancer cells","volume":"12","author":"McCubrey","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.jbior.2022.100917_bib49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1158\/1078-0432.CCR-21-3382","article-title":"BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): a Phase I\/II trial of dabrafenib, trametinib, and hydroxychloroquine in advanced BRAFV600-mutant melanoma","volume":"28","author":"Mehnert","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbior.2022.100917_bib50","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.4161\/auto.32135","article-title":"Regulation of autophagy and chloroquine sensitivity by oncogenic RAS in vitro is context-dependent","volume":"10","author":"Morgan","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.jbior.2022.100917_bib51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000510343","article-title":"Neoadjuvant chemotherapy in pancreatic cancer: an appraisal of the current high-level evidence","volume":"106","author":"M\u00fcller","year":"2021","journal-title":"Pharmacology"},{"key":"10.1016\/j.jbior.2022.100917_bib52","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.disamonth.2013.08.001","article-title":"Pancreatic cancer: a comprehensive review and update","volume":"59","author":"Muniraj","year":"2013","journal-title":"Disease-a-Month: DM."},{"key":"10.1016\/j.jbior.2022.100917_bib53","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1038\/oncsis.2016.40","article-title":"Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death","volume":"5","author":"Nakamura","year":"2016","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jbior.2022.100917_bib54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13014-019-1345-6","article-title":"Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches","volume":"14","author":"Orth","year":"2019","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2015.12.017","article-title":"Time to use a dose of chloroquine as an adjuvant to anti-cancer chemotherapies","volume":"771","author":"Pascolo","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jbior.2022.100917_bib56","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41416-020-01039-5","article-title":"Autophagy as a therapeutic target in pancreatic cancer","volume":"124","author":"Piffoux","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbior.2022.100917_bib57","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/atm.2019.10.91","article-title":"Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment","volume":"7","author":"Pu","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.jbior.2022.100917_bib58","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Qian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/2159-8290.CD-18-0706","article-title":"PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer","volume":"9","author":"Rebecca","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jbior.2022.100917_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/cancers10010016","article-title":"Locally advanced pancreatic cancer: a review of local ablative therapies","volume":"10","author":"Ruarus","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.jbior.2022.100917_bib61","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189051","article-title":"Reprogramming pancreatic stellate cells via p53 activation: a putative target for pancreatic cancer therapy","volume":"12","author":"Saison-Ridinger","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jbior.2022.100917_bib62","article-title":"Autophagy modulation and cancer combination therapy: a smart approach in cancer therapy","volume":"30","author":"Salimi-Jeda","year":"2022","journal-title":"Cancer Treat. Res. Com."},{"key":"10.1016\/j.jbior.2022.100917_bib63","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3324\/haematol.2020.249060","article-title":"To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia","volume":"105","author":"Sallman","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jbior.2022.100917_bib64","first-page":"1584","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.jbior.2022.100917_bib65","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00280-017-3446-y","article-title":"Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer","volume":"80","author":"Samaras","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jbior.2022.100917_bib66","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/0008-5472.CAN-21-1443","article-title":"Concurrent inhibition of IGF1R and ERK increases pancreatic cancer sensitivity to autophagy inhibitors","volume":"82","author":"Stalnecker","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbior.2022.100917_bib67","doi-asserted-by":"crossref","first-page":"560","DOI":"10.2174\/138161211795222603","article-title":"Pharmacologic activation of p53 by small-molecule MDM2 antagonists","volume":"17","author":"Shen","year":"2011","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.jbior.2022.100917_bib68","first-page":"11","article-title":"Cancer statistics","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.jbior.2022.100917_bib69","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-144-5-200603070-00008","article-title":"Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial","volume":"144","author":"Sotelo","year":"2006","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.jbior.2022.100917_bib70","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-017-0500-5","article-title":"MDM2\/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer","volume":"10","author":"Tisato","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib71","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-019-05489-1","article-title":"HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies","volume":"179","author":"Tracey","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.jbior.2022.100917_bib72","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1002\/ijc.31603","article-title":"Phase I\/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer","volume":"143","author":"Van Cutsem","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbior.2022.100917_bib73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/imm.13160","article-title":"Dissecting pharmacological effects of chloroquine in cancer treatment: interference with inflammatory signaling pathways","volume":"159","author":"Varisli","year":"2020","journal-title":"Immunol."},{"key":"10.1016\/j.jbior.2022.100917_bib74","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","author":"Waters","year":"2018","journal-title":"CSH Pre. Med"},{"key":"10.1016\/j.jbior.2022.100917_bib75","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fonc.2018.00335","article-title":"Re-purposing chloroquine for glioblastoma: potential merits and confounding variables","volume":"8","author":"Weyerh\u00e4user","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1634\/theoncologist.2014-0086","article-title":"Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma","volume":"19","author":"Wolpin","year":"2014","journal-title":"Oncol."},{"key":"10.1016\/j.jbior.2022.100917_bib77","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/ijms22010179","article-title":"The dual role of autophagy in cancer development and a therapeutic strategy for cancer by targeting autophagy","volume":"22","author":"Yun","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jbior.2022.100917_bib78","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1185\/03007995.2015.1025731","article-title":"The utility of chloroquine in cancer therapy","volume":"31","author":"Zhang","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jbior.2022.100917_bib79","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-017-0551-7","article-title":"Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions","volume":"11","author":"Zhang","year":"2016","journal-title":"J. Hematol. Oncol."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492622000574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492622000574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:31:04Z","timestamp":1761949864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492622000574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":78,"alternative-id":["S2212492622000574"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2022.100917","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of chloroquine and hydroxychloroquine on the sensitivity of pancreatic cancer cells to targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2022.100917","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100917"}}